Search
for
Sort by
Research 61–90 of 536
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
- Molecular Predictors of Ritlecitinib Efficacy in Alopecia Areata: Role of JAK3-Dependent Inflammation and Follicular Integrity
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Selective blockade of γc pathway ameliorates alopecia areata in a humanized murine model
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- “<i>Nomen Omen</i>: The Myth of God Janus”
- INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Repigmentation Competence in Vitiligo: Integrating Immune, Regulatory, Regenerative, and Microenvironmental Axes
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Alopecia Areata: Pathogenesis, current treatments, and future perspectives
- Dermal T cell immunity and key regulatory signaling pathways: Implications in immune-mediated alopecia and hair regeneration
- Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- Real-world evidence in alopecia areata treatment: A narrative review
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- The Possible Role of Antibodies in Alopecia: A Narrative Review
- Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata